Four Indian generic companies take sub license from MPP on daclatasvir

Four Indian generic companies take sub license from MPP on daclatasvir

Four Indian generic companies (Cipla, Emcure, Hetero and NATCO) takes sub-licenses from Medicines Patent pool (MPP) on Daclatasvir. The copy of the sub- licenses are not available yet, but please refer to the form for an outline. Long term implications of how this improves access in included territory or inhibits the same in excluded territory is to be seen soon.

Click here for more details.

/ News

Share the Post